Paolo Bellantonio
Overview
Explore the profile of Paolo Bellantonio including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
291
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Iaffaldano P, Lucisano G, Guerra T, Paolicelli D, Portaccio E, Inglese M, et al.
Ann Clin Transl Neurol
. 2024 Jul;
11(8):2008-2015.
PMID: 38970214
Objective: No direct comparisons of the effect of natalizumab and ocrelizumab on progression independent of relapse activity (PIRA) and relapse-associated worsening (RAW) events are currently available. We aimed to compare...
2.
Iaffaldano P, Lucisano G, Guerra T, Patti F, Cocco E, De Luca G, et al.
J Neurol
. 2023 Dec;
271(3):1150-1159.
PMID: 38135850
Background: Active relapsing-remitting (RR) and secondary progressive (SP) multiple sclerosis (MS) are currently defined as "relapsing MS" (RMS). The aim of this cross-sectional study was to assess drivers of treatment...
3.
Zanghi A, Galgani S, Bellantonio P, Zaffaroni M, Borriello G, Inglese M, et al.
Eur J Neurol
. 2023 Jun;
30(9):2736-2744.
PMID: 37294976
Background And Purpose: The overall disability in patients with relapsing-remitting multiple sclerosis is likely to be partly rather than entirely attributed to relapse. Materials And Methods: The aim was to...
4.
Gilio L, Fresegna D, Gentile A, Guadalupi L, Sanna K, Vito F, et al.
Neurobiol Dis
. 2022 Jul;
172:105817.
PMID: 35835361
Background: Elevated levels of specific proinflammatory molecules in the cerebrospinal fluid (CSF) have been associated with disability progression, enhanced neurodegeneration and higher incidence of mood disorders in people with multiple...
5.
Stampanoni Bassi M, Gilio L, Iezzi E, Moscatelli A, Pekmezovic T, Drulovic J, et al.
Front Aging Neurosci
. 2021 Sep;
13:694651.
PMID: 34566620
Age at onset is the main risk factor for disease progression in patients with relapsing-remitting multiple sclerosis (RR-MS). In this cross-sectional study, we explored whether older age is associated with...
6.
Stampanoni Bassi M, Nuzzo T, Gilio L, Miroballo M, Casamassa A, Buttari F, et al.
J Neurochem
. 2021 Sep;
159(5):857-866.
PMID: 34547109
Excessive extracellular concentrations of L-glutamate (L-Glu) can be neurotoxic and contribute to neurodegenerative processes in multiple sclerosis (MS). The association between cerebrospinal fluid (CSF) L-Glu levels, clinical features, and inflammatory...
7.
Chisari C, Comi G, Filippi M, Paolicelli D, Iaffaldano P, Zaffaroni M, et al.
J Neurol
. 2021 Jun;
269(2):933-944.
PMID: 34181077
Background: Natalizumab (NTZ) is an effective treatment for relapsing-remitting multiple sclerosis (RRMS). However, patients and physicians may consider discontinuing NTZ therapy due to safety or efficacy issues. The aim of...
8.
Iaffaldano P, Lucisano G, Caputo F, Paolicelli D, Patti F, Zaffaroni M, et al.
Ther Adv Neurol Disord
. 2021 Jun;
14:17562864211019574.
PMID: 34104220
Background And Aims: No consensus exists on how aggressively to treat relapsing-remitting multiple sclerosis (RRMS) nor on the timing of the treatment. The objective of this study was to evaluate...
9.
Buttari F, Bruno A, Dolcetti E, Azzolini F, Bellantonio P, Centonze D, et al.
Mult Scler Relat Disord
. 2021 May;
52:102983.
PMID: 33990054
Since the recent approval of vaccines against COVID-19, efficacy concerns emerged for MS patients treated with immunosuppressive drugs. We report our experience in four patients, under cladribine (two) or under...
10.
Stampanoni Bassi M, Drulovic J, Pekmezovic T, Iezzi E, Sica F, Gilio L, et al.
Ther Adv Neurol Disord
. 2020 Dec;
13:1756286420970833.
PMID: 33343708
Background And Aims: Interferon beta (IFNb) is a safe first-line drug commonly used for relapsing-remitting (RR)-MS. Nevertheless, a considerable proportion of patients do not respond to IFNb treatment. Therefore, until...